clinical trial · NCT07221344
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Alzheimer DiseaseAlzheimer Disease, Early OnsetARO-MAPT-SCPlacebo
brief summary
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
started
Nov 18, 2025
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Apr 15, 2026
official title
A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol